These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28617833)

  • 1. Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.
    Sailer V; Gevensleben H; Dietrich J; Goltz D; Kristiansen G; Bootz F; Dietrich D
    PLoS One; 2017; 12(6):e0179412. PubMed ID: 28617833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma.
    Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; de Vos L; Franzen A; Schröck F; Bootz F; Kristiansen G; Schröck A; Dietrich D
    Oncotarget; 2016 Nov; 7(46):75827-75838. PubMed ID: 27716615
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Sailer V; Holmes EE; Gevensleben H; Goltz D; Dröge F; Franzen A; Dietrich J; Kristiansen G; Bootz F; Schröck A; Dietrich D
    Clin Epigenetics; 2017; 9():12. PubMed ID: 28174607
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Holmes EE; Goltz D; Sailer V; Jung M; Meller S; Uhl B; Dietrich J; Röhler M; Ellinger J; Kristiansen G; Dietrich D
    Clin Epigenetics; 2016; 8():104. PubMed ID: 27708722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intragenic DNA methylation of PITX1 and the adjacent long non-coding RNA C5orf66-AS1 are prognostic biomarkers in patients with head and neck squamous cell carcinomas.
    Sailer V; Charpentier A; Dietrich J; Vogt TJ; Franzen A; Bootz F; Dietrich D; Schroeck A
    PLoS One; 2018; 13(2):e0192742. PubMed ID: 29425237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of PITX2 Promoter Methylation in Colorectal Carcinoma Prognosis.
    Semaan A; Uhl B; Branchi V; Lingohr P; Bootz F; Kristiansen G; Kalff JC; Matthaei H; Pantelis D; Dietrich D
    Clin Colorectal Cancer; 2018 Jun; 17(2):e385-e393. PubMed ID: 29580650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation of PITX2 predicts poor survival in men with prostate cancer.
    Vasiljević N; Ahmad AS; Carter PD; Fisher G; Berney DM; Foster CS; Cuzick J; Lorincz AT
    Biomark Med; 2014; 8(9):1143-50. PubMed ID: 25402584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients.
    Dietrich D; Hasinger O; Liebenberg V; Field JK; Kristiansen G; Soltermann A
    Diagn Mol Pathol; 2012 Jun; 21(2):93-104. PubMed ID: 22555092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients.
    Dietrich D; Weider S; de Vos L; Vogt TJ; Färber M; Zarbl R; Hunecke A; Glosch AK; Gabrielpillai J; Bootz F; Bauernfeind FG; Kramer FJ; Kristiansen G; Brossart P; Strieth S; Franzen A
    Clin Chem; 2023 Sep; 69(9):1050-1061. PubMed ID: 37477541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients.
    Nimmrich I; Sieuwerts AM; Meijer-van Gelder ME; Schwope I; Bolt-de Vries J; Harbeck N; Koenig T; Hartmann O; Kluth A; Dietrich D; Magdolen V; Portengen H; Look MP; Klijn JG; Lesche R; Schmitt M; Maier S; Foekens JA; Martens JW
    Breast Cancer Res Treat; 2008 Oct; 111(3):429-37. PubMed ID: 17965955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract.
    Uhl B; Dietrich D; Branchi V; Semaan A; Schaefer P; Gevensleben H; Rostamzadeh B; Lingohr P; Schäfer N; Kalff JC; Kristiansen G; Matthaei H
    PLoS One; 2016; 11(10):e0165769. PubMed ID: 27798672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic and predictive methylation biomarkers in HNSCC : Epigenomic diagnostics for head and neck squamous cell carcinoma (HNSCC)].
    Franzen A; Bootz F; Dietrich D
    HNO; 2020 Dec; 68(12):911-915. PubMed ID: 32613323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.
    Uhl B; Gevensleben H; Tolkach Y; Sailer V; Majores M; Jung M; Meller S; Stein J; Ellinger J; Dietrich D; Kristiansen G
    J Mol Diagn; 2017 Jan; 19(1):107-114. PubMed ID: 27939865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance.
    Carvalho AL; Henrique R; Jeronimo C; Nayak CS; Reddy AN; Hoque MO; Chang S; Brait M; Jiang WW; Kim MM; Claybourne Q; Goldenberg D; Khan Z; Khan T; Westra WH; Sidransky D; Koch W; Califano JA
    Clin Cancer Res; 2011 Jul; 17(14):4782-9. PubMed ID: 21628494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas.
    Virani S; Bellile E; Bradford CR; Carey TE; Chepeha DB; Colacino JA; Helman JI; McHugh JB; Peterson LA; Sartor MA; Taylor JM; Walline HM; Wolf GT; Rozek LS
    BMC Cancer; 2015 Oct; 15():825. PubMed ID: 26518708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. X-linked FHL1 as a novel therapeutic target for head and neck squamous cell carcinoma.
    Cao W; Liu J; Xia R; Lin L; Wang X; Xiao M; Zhang C; Li J; Ji T; Chen W
    Oncotarget; 2016 Mar; 7(12):14537-50. PubMed ID: 26908444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation biomarkers for head and neck squamous cell carcinoma.
    Zhou C; Ye M; Ni S; Li Q; Ye D; Li J; Shen Z; Deng H
    Epigenetics; 2018; 13(4):398-409. PubMed ID: 29927694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PITX2: a promising predictive biomarker of patients' prognosis and chemoradioresistance in esophageal squamous cell carcinoma.
    Zhang JX; Tong ZT; Yang L; Wang F; Chai HP; Zhang F; Xie MR; Zhang AL; Wu LM; Hong H; Yin L; Wang H; Wang HY; Zhao Y
    Int J Cancer; 2013 Jun; 132(11):2567-77. PubMed ID: 23132660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
    Zhou C; Shen Z; Ye D; Li Q; Deng H; Liu H; Li J
    Cell Physiol Biochem; 2018; 50(3):868-882. PubMed ID: 30355925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.